Abivax SA Sponsored ADR (NASDAQ:ABVX - Get Free Report) shares saw strong trading volume on Monday . 230,917 shares traded hands during mid-day trading, an increase of 19% from the previous session's volume of 193,858 shares.The stock last traded at $10.33 and had previously closed at $9.95.
Wall Street Analysts Forecast Growth
ABVX has been the topic of a number of recent research reports. JMP Securities set a $33.00 price objective on shares of Abivax in a report on Friday. Citigroup reaffirmed a "market outperform" rating on shares of Abivax in a research note on Friday. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Abivax presently has a consensus rating of "Buy" and a consensus price target of $31.00.
Check Out Our Latest Stock Analysis on Abivax
Abivax Trading Up 2.7%
The company has a 50 day moving average of $7.14 and a 200-day moving average of $6.80. The company has a current ratio of 1.25, a quick ratio of 1.25 and a debt-to-equity ratio of 1.29.
Hedge Funds Weigh In On Abivax
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Woodline Partners LP lifted its position in Abivax by 319.5% in the 1st quarter. Woodline Partners LP now owns 201,924 shares of the company's stock valued at $1,262,000 after acquiring an additional 153,788 shares in the last quarter. Octagon Capital Advisors LP bought a new stake in shares of Abivax during the 1st quarter valued at $7,688,000. Millennium Management LLC boosted its stake in shares of Abivax by 6.0% during the 1st quarter. Millennium Management LLC now owns 987,414 shares of the company's stock worth $6,171,000 after purchasing an additional 56,235 shares during the period. Allostery Investments LP raised its stake in shares of Abivax by 86.0% during the 1st quarter. Allostery Investments LP now owns 1,099,654 shares of the company's stock worth $6,873,000 after acquiring an additional 508,401 shares in the last quarter. Finally, ADAR1 Capital Management LLC increased its stake in shares of Abivax by 46.0% in the first quarter. ADAR1 Capital Management LLC now owns 2,210,019 shares of the company's stock worth $13,813,000 after acquiring an additional 696,626 shares during the period. 47.91% of the stock is owned by institutional investors.
About Abivax
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Abivax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.
While Abivax currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
